Netupitant; palonosetron hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for netupitant; palonosetron hydrochloride and what is the scope of patent protection?
Netupitant; palonosetron hydrochloride
is the generic ingredient in one branded drug marketed by Helsinn Hlthcare and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.Netupitant; palonosetron hydrochloride has seventy-six patent family members in forty-one countries.
One supplier is listed for this compound.
Summary for netupitant; palonosetron hydrochloride
International Patents: | 76 |
US Patents: | 12 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 17 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for netupitant; palonosetron hydrochloride |
DailyMed Link: | netupitant; palonosetron hydrochloride at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for netupitant; palonosetron hydrochloride
Generic Entry Date for netupitant; palonosetron hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for netupitant; palonosetron hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sichuan Cancer Hospital and Research Institute | N/A |
Helsinn Healthcare SA | Phase 4 |
Instituto Brasileiro de Controle do Cancer | Phase 2 |
See all netupitant; palonosetron hydrochloride clinical trials
Pharmacology for netupitant; palonosetron hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Helsinn Hlthcare | AKYNZEO | netupitant; palonosetron hydrochloride | CAPSULE;ORAL | 205718-001 | Oct 10, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Helsinn Hlthcare | AKYNZEO | netupitant; palonosetron hydrochloride | CAPSULE;ORAL | 205718-001 | Oct 10, 2014 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for netupitant; palonosetron hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2727590 | Compositions pour traiter les nausées et vomissements à médiation centrale (Compositions for treating centrally mediated nausea and vomiting) | ⤷ Sign Up |
Ukraine | 105817 | КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ТОШНОТЫ И РВОТЫ ЦЕНТРАЛЬНОГО ПРОИСХОЖДЕНИЯ;КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ НУДОТИ І БЛЮВАННЯ ЦЕНТРАЛЬНОГО ПОХОДЖЕННЯ (Normal;heading 1;heading 2;heading 3;COMPOSITIONS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING) | ⤷ Sign Up |
China | 102655864 | Compositions and methods for treating centrally mediated nausea and vomiting | ⤷ Sign Up |
Australia | 2010320598 | Compositions for treating centrally mediated nausea and vomiting | ⤷ Sign Up |
San Marino | T201600427 | COMPOSIZIONI PER TRATTARE NAUSEA E VOMITO MEDIATI A LIVELLO CENTRALE | ⤷ Sign Up |
European Patent Office | 2361090 | COMPOSITIONS POUR TRAITER LES NAUSÉES ET VOMISSEMENTS À MÉDIATION CENTRALE (COMPOSITIONS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for netupitant; palonosetron hydrochloride
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2785706 | 2090015-5 | Sweden | ⤷ Sign Up | PRODUCT NAME: FOSNETUPITANT; REG. NO/DATE: EU/1/15/1001 20200317 |
1035115 | CR 2015 00044 | Denmark | ⤷ Sign Up | PRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529 |
2785706 | SPC/GB20/037 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FOSNETUPITANT; REGISTERED: UK EU/1/15/1001 (NI) 20200318; UK PLGB 12333/0017-0001 20200318 |
1035115 | C01035115/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: NETUPITANT; REGISTRATION NO/DATE: SWISSMEDIC 65499 06.11.2015 |
2785706 | 20C1029 | France | ⤷ Sign Up | PRODUCT NAME: FOSNETUPITANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SEL DE CHLORHYDRATE DE CHLORURE DE FOSNETUPITANT; REGISTRATION NO/DATE: EU/1/15/1001 20200318 |
2785706 | C20200029 00371 | Estonia | ⤷ Sign Up | PRODUCT NAME: FOSNETUPITANT;REG NO/DATE: EU/1/15/1001; 18.03.2020 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.